Highly-effective CFTR modulators such as Elexacaftor/Tezacaftor/Ivacaftor (Trikafta®) and Ivacaftor (Kalydeco®) are the most effective treatment options for eligible individuals with CF and they have the potential to prevent moderate-to-severe lung disease if initiated earlier in life67,68. This evidence concerns the gene CFTR and lung disorder.